fda glp-1 warning news september 2025 2, 2025: U.S. compounding restrictions have stemmed a flood of compounded semaglutide and tirzepatide – Partnership for Safe Medicines FDA Drug Recalls and Warnings:

In conclusion, preclinical and emerging clinical evidence are changing the paradigm, viewing incretin receptor agonists solely as metabolic-based therapeutics for treating obesity and diabetes to recognising them as multifaceted agents with significant disease-modifying potential for inflammatory fibrotic disorders across different organ systems

A new ferroptosis-related signature model including messenger RNAs and long non-coding RNAs predicts the prognosis of gastric cancer patients

Does PlexusDx compounded semaglutide cost extra if I need dose increases

phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data

Its therapeutic value lies in its ability to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 interactome, a mechanism that evades the collateral cytotoxicity often seen with broader senolytics like Navitoclax (Huang et al., 2021)